ライフサイエンスコーパス: vasoactive intestinal polypeptide

1 P) as a second messenger (e.g., secretin and vasoactive intestinal polypeptide).

2 the SCN: AVP (arginine vasopressin) and VIP (vasoactive intestinal polypeptide).

3 toxin-insensitive G(s)-coupled receptors for vasoactive intestinal polypeptide.

4 tion in response to sodium nitroprusside and vasoactive intestinal polypeptide.

5 Rs that do not distinguish between PACAP and vasoactive intestinal polypeptide.

6 a response not elicited by stimulation with vasoactive intestinal polypeptide.

7 sequence homology with both PACAP-27/38 and vasoactive intestinal polypeptide.

8 dal cells and GABA interneurons coexpressing vasoactive intestinal polypeptide.

9 injured unmyelinated afferents labeled with vasoactive intestinal polypeptide.

10 rtical interneurons express either Reelin or vasoactive intestinal polypeptide.

11 hese also contained nitric oxide synthase or vasoactive intestinal polypeptide.

12 AC receptor homo-oligomers were modulated by vasoactive intestinal polypeptide.

13 Vasoactive intestinal polypeptide (60 nmol/L), acetylcho

14 ehavior, combined with genetic disruption of vasoactive intestinal polypeptide, a key SCN signaling m

15 normal electrophysiology in the presence of vasoactive intestinal polypeptide, a potent stimulator o

16 interneuron-specific (I-S3) cells expressing vasoactive intestinal polypeptide and calretinin play a

17 al afferents, and contains neurons producing vasoactive intestinal polypeptide and gastrin-releasing

18 er, GTP gamma S binding induced by CCK-8 and vasoactive intestinal polypeptide and the binding capaci

19 The VPAC(1) and VPAC(2) receptors for vasoactive intestinal polypeptide and the PAC(1) recepto

20 ceptor or of the neuropeptides somatostatin, vasoactive intestinal polypeptide, and choleocystokinin.

21 s variant gene 1, substance P, somatostatin, vasoactive intestinal polypeptide, and parvalbumin.

22 neurons contained the inhibitory transmitter vasoactive intestinal polypeptide, and some were immunor

23 nolol, methysergide, substance P antagonist, vasoactive intestinal polypeptide antagonist, apamin, an

24 found in SCN cells, arginine vasopressin and vasoactive intestinal polypeptide appeared to be in cont

25 and the receptors for prostaglandin E(2) and vasoactive intestinal polypeptide, are not expressed or

26 AC1-VPAC2 hetero-oligomers were modulated by vasoactive intestinal polypeptide binding, whereas the s

27 co-localize with either cholecystokinin- or vasoactive intestinal polypeptide, but does with vasopre

28 n at least acetylcholine, adrenergic agents, vasoactive intestinal polypeptide, calcitonin gene-relat

29 tives between somatostatin, parvalbumin, and vasoactive intestinal polypeptide cells.

30 pressing cyclooxygenase-2 (22%, p < 0.05) or vasoactive intestinal polypeptide-containing interneuron

31 unctions such as motility and secretion (eg, vasoactive intestinal polypeptide, cystic fibrosis trans

32 It has been demonstrated that vasoactive intestinal polypeptide, epidermal growth fact

33 We report that vasoactive intestinal polypeptide, epidermal growth fact

34 goal-oriented learning tasks, we found that vasoactive intestinal polypeptide-expressing (VIP(+)), d

35 Touch only weakly modulated vasoactive intestinal polypeptide-expressing (VIP) inter

36 re, we used a transgenic mouse line in which vasoactive intestinal polypeptide-expressing (VIP+) GABA

37 tory neurons reduced their activity, whereas vasoactive intestinal polypeptide-expressing interneuron

38 These neurons directly activate vasoactive intestinal polypeptide-expressing interneuron

39 These preferentially inhibit vasoactive intestinal polypeptide-expressing interneuron

40 at in contrast to somatostatin-expressing or vasoactive intestinal polypeptide-expressing interneuron

41 we have confirmed an indispensable role for vasoactive intestinal polypeptide-expressing SCN (SCN(VI

42 ubstance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide, galanin, somatostatin

43 bodies with immunoreactive (IR) vasopressin, vasoactive intestinal polypeptide, gastrin-releasing pep

44 Immunostaining for vasoactive intestinal polypeptide-immunoreactive parasym

45 Vasoactive intestinal polypeptide immunoreactivity was f

46 signaling pathways induced by kisspeptin and vasoactive intestinal polypeptide in GnRH neuronal cell

47 for the specification of neuropeptide Y and vasoactive intestinal polypeptide, indicating that a sub

48 Vasoactive intestinal polypeptide may be the molecule th

49 ndin, calretinin, parvalbumin, somatostatin, vasoactive intestinal polypeptide, neuropeptide Y, or ch

50 Immunoreactivity for vasoactive intestinal polypeptide, nitric oxide synthase

51 ic neuropeptides was distinct, with abundant vasoactive intestinal polypeptide observed in human but

52 Vasoactive intestinal polypeptide operated via protein k

53 ons, but not nonpyramidal neurons containing vasoactive intestinal polypeptide or neuropeptide Y.

54 light acting weakly upon a strongly rhythmic vasoactive intestinal polypeptide oscillation can explai

55 Although locomotion-induced vasoactive intestinal polypeptide positive (VIP) interne

56 nitric oxide synthase (eNOS)-expressing and vasoactive intestinal polypeptide-positive enteric neuro

57 inergic, adrenergic, and nitrergic axons and vasoactive intestinal polypeptide-positive terminals, so

58 ealed an abnormal number and distribution of vasoactive intestinal polypeptide-producing neurons, sug

59 d by agonists such as prostaglandin E(2) and vasoactive intestinal polypeptide, promotes proliferatio

60 function, including cholinergic, adrenergic, vasoactive intestinal polypeptide, purinergic, androgen,

61 Vasoactive intestinal polypeptide receptor (VIP1R) is a

62 The transcriptional repressor for rat vasoactive intestinal polypeptide receptor 1 (VIPR-RP) i

63 Here, we show that subtypes of human vasoactive intestinal polypeptide receptors (VPAC1 and V

64 in, or with thyrotropin releasing hormone or vasoactive intestinal polypeptide resulted in abundant e

65 Acetylcholine, isoproterenol, and vasoactive intestinal polypeptide significantly stimulat

66 phorbol ester, epidermal growth factor, and vasoactive intestinal polypeptide stimulated p38 MAP kin

67 e exchange of action potentials that release vasoactive intestinal polypeptide, striking a compromise

68 gene-related peptide, tyrosine hydroxylase, vasoactive intestinal polypeptide, substance P, corticot

69 y preabsorption of PACAP-27/38 antisera with vasoactive intestinal polypeptide, suggesting that a sub

70 In contrast, vasoactive intestinal polypeptide-, TK-, choline acetylt

71 oxylase, neuronal nitric oxide synthase, and vasoactive intestinal polypeptide to visualize neural el

72 de for two other members of this family, the vasoactive intestinal polypeptide type 1 and calcitonin

73 The vasoactive intestinal polypeptide type-1 (VPAC(1)) recep

74 (MT), corticotropin-releasing hormone (CRH), vasoactive intestinal polypeptide, tyrosine hydroxylase,

75 We demonstrate that interneurons expressing vasoactive intestinal polypeptide (VIP(+)) play a causal

76 Here, we show that interneurons expressing vasoactive intestinal polypeptide (VIP(+)) regulate the

77 of two neuropeptides synthesized in the SCN, vasoactive intestinal polypeptide (VIP) and arginine vas

78 hat type 3 IS (IS3) cells that coexpress the vasoactive intestinal polypeptide (VIP) and calretinin c

79 th light microscopic immunocytochemistry for vasoactive intestinal polypeptide (VIP) and cytoarchitec

80 -dependent coupling process mediated by both vasoactive intestinal polypeptide (VIP) and GABAA signal

81 The neuropeptide vasoactive intestinal polypeptide (VIP) and its VPAC2 re

82 also simulated clock phase shifts induced by vasoactive intestinal polypeptide (VIP) and matched expe

83 opalatine ganglion, which appears to utilize vasoactive intestinal polypeptide (VIP) and nitric oxide

84 an serous cells secrete fluid in response to vasoactive intestinal polypeptide (VIP) and other agents

85 adenomas, we investigated the expression of vasoactive intestinal polypeptide (VIP) and PACAP bindin

86 Vasoactive intestinal polypeptide (VIP) and pituitary ad

87 s this cyclic information to GnRH neurons is vasoactive intestinal polypeptide (VIP) and that it may

88 een the pelvic visceral afferent transmitter vasoactive intestinal polypeptide (VIP) and the delta-op

89 Vasoactive intestinal polypeptide (VIP) and the VIP rece

90 e used to ascertain the relationship between vasoactive intestinal polypeptide (VIP) and tyrosine hyd

91 L-arginine methyl ester (L-NAME), but not by vasoactive intestinal polypeptide (VIP) antiserum, guane

92 r AVD is a redundant system in which ACh and vasoactive intestinal polypeptide (VIP) are co-released

93 Inhibitory interneurons expressing vasoactive intestinal polypeptide (VIP) are known to dis

94 recent data implicating the neurotransmitter vasoactive intestinal polypeptide (VIP) as the key synch

95 racellular cAMP, was sufficient to stimulate vasoactive intestinal polypeptide (VIP) biosynthesis at

96 Extending the secretin-vasoactive intestinal polypeptide (VIP) chimeric recepto

97 ) of an antibody raised by immunization with vasoactive intestinal polypeptide (VIP) cleaved this pep

98 , we investigated whether the projections of vasoactive intestinal polypeptide (VIP) from the SCN to

99 olar infusion of the VPAC1/2 receptor ligand vasoactive intestinal polypeptide (VIP) had no effect on

100 Vasoactive intestinal polypeptide (VIP) has also been sh

101 The peptide neurotransmitter vasoactive intestinal polypeptide (VIP) has several impo

102 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) have been found

103 e cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) immunoreactive (

104 K), and receive input from galanin (GAL) and vasoactive intestinal polypeptide (VIP) immunoreactive f

105 ked sexual dimorphism in the distribution of vasoactive intestinal polypeptide (VIP) immunoreactive f

106 Recent evidence suggests a role for vasoactive intestinal polypeptide (VIP) in active vasodi

107 d determine the role of mast cells (MCs) and vasoactive intestinal polypeptide (VIP) in barrier regul

108 were immunoreactive for vasopressin (AVP) or vasoactive intestinal polypeptide (VIP) in wild type and

109 Vasodilatory nerve fibers containing vasoactive intestinal polypeptide (VIP) innervate choroi

110 and alpha5-knockout mice, lower activity of vasoactive intestinal polypeptide (VIP) interneurons res

111 s: somatostatin (SST), parvalbumin (PV), and vasoactive intestinal polypeptide (VIP) interneurons.

112 Vasoactive intestinal polypeptide (VIP) is a neuropeptid

113 Vasoactive intestinal polypeptide (VIP) is an intrinsic

114 Although vasoactive intestinal polypeptide (VIP) is critical for

115 Vasoactive intestinal polypeptide (VIP) is distributed i

116 In mammals, vasoactive intestinal polypeptide (VIP) is known to have

117 Vasoactive intestinal polypeptide (VIP) is released from

118 ow that a class of interneurons that express vasoactive intestinal polypeptide (VIP) mediates disinhi

119 Previous data suggested vasoactive intestinal polypeptide (VIP) might be contain

120 we show in mice that neuromedin S (NMS) and vasoactive intestinal polypeptide (VIP) neurons in the S

121 Vasoactive intestinal polypeptide (VIP) neurons were sig

122 upled via gamma-aminobutyric acid (GABA) and vasoactive intestinal polypeptide (VIP) neurotransmitter

123 The effects of vasoactive intestinal polypeptide (VIP) on isolated para

124 l (PYR) neuron activation, excitation of the vasoactive intestinal polypeptide (VIP) or inhibition of

125 e imaging, we show that SCN cells expressing vasoactive intestinal polypeptide (VIP) or its cognate r

126 ssion and odor detection performance require vasoactive intestinal polypeptide (VIP) or its receptor

127 that contained arginine vasopressin (AVP) or vasoactive intestinal polypeptide (VIP) or neither.

128 There is evidence that vasoactive intestinal polypeptide (VIP) participates in

129 nd these constituted a sub-population of the vasoactive intestinal polypeptide (VIP) positive cells.

130 ampal neurons in culture to demonstrate that vasoactive intestinal polypeptide (VIP) promotes neurona

131 All splice variants of PAC1 were found, but vasoactive intestinal polypeptide (VIP) receptor (VPAC)

132 The type 1 vasoactive intestinal polypeptide (VIP) receptor gene is

133 Both secretin and vasoactive intestinal polypeptide (VIP) receptors are re

134 Vasoactive intestinal polypeptide (VIP) relaxes smooth m

135 Vasoactive intestinal polypeptide (VIP) signaling is cri

136 In particular, while vasoactive intestinal polypeptide (VIP) signalling is es

137 ne hydroxylase, nitric oxide synthetase, and vasoactive intestinal polypeptide (VIP) to detect neural

138 Neurones immunoreactive for vasoactive intestinal polypeptide (VIP) were studied in

139 Strikingly, vasoactive intestinal polypeptide (VIP), a neuropeptide

140 Paradoxically, we found that vasoactive intestinal polypeptide (VIP), a neuropeptide

141 ansmission was simulated via the addition of vasoactive intestinal polypeptide (VIP), a pelvic viscer

142 OR myenteric neurons were immunoreactive for vasoactive intestinal polypeptide (VIP), and about 31% w

143 ce labeling for nitric oxide synthase (NOS), vasoactive intestinal polypeptide (VIP), and choline ace

144 ronal activity dynamics of parvalbumin (PV), vasoactive intestinal polypeptide (VIP), and somatostati

145 rneurons expressing neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP), and the numeric

146 ne-related peptide (CGRP), substance P (SP), vasoactive intestinal polypeptide (VIP), and tyrosine hy

147 sine hydroxylase (TH), neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP), calcitonin gene

148 e (nNOS), choline acetyl transferase (ChAT), vasoactive intestinal polypeptide (VIP), calcitonin gene

149 presence and colocalization of the peptides vasoactive intestinal polypeptide (VIP), calcitonin-gene

150 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP), on ECL cell pro

151 Vasoactive intestinal polypeptide (VIP), pituitary adeny

152 r GnIH inhibits the action of kisspeptin and vasoactive intestinal polypeptide (VIP), positive regula

153 neurons in mice, including those expressing vasoactive intestinal polypeptide (VIP), somatostatin (S

154 e suprachiasmatic nucleus (SCN) that express vasoactive intestinal polypeptide (VIP), which are criti

155 The pattern of distribution of vasoactive intestinal polypeptide (VIP)- and tyrosine hy

156 the nucleus characterized by a population of vasoactive intestinal polypeptide (VIP)-containing neuro

157 circuit in frontal cortex that originates in vasoactive intestinal polypeptide (VIP)-expressing inter

158 ously, we identified a cortical neuron type, vasoactive intestinal polypeptide (VIP)-expressing inter

159 parvalbumin (PV)-, somatostatin (SST)-, and vasoactive intestinal polypeptide (VIP)-expressing inter

160 , but not that of somatostatin-expressing or vasoactive intestinal polypeptide (VIP)-expressing inter

161 of somatostatin (SST)-expressing neurons by vasoactive intestinal polypeptide (VIP)-expressing neuro

162 environmental dynamics, we examined roles of vasoactive intestinal polypeptide (VIP)-expressing neuro

163 OS)-, choline acetyltransferase (ChAT)-, and vasoactive intestinal polypeptide (VIP)-immunoreactiviti

164 stance P (SP)-IR varicosities and 9 +/- 1.3% vasoactive intestinal polypeptide (VIP)-IR varicosities

165 ion-induced release of substance P (SP)- and vasoactive intestinal polypeptide (VIP)-like immunoreact

166 d was expressed in 7-12% of cells containing vasoactive intestinal polypeptide (VIP).

167 piperazinium iodide (DMPP), and neuropeptide vasoactive intestinal polypeptide (VIP).

168 erated against vertebrate retinal opsins and vasoactive intestinal polypeptide (VIP).

169 tion, sensory neurons preferentially release vasoactive intestinal polypeptide (VIP).

170 somedial (DM) shell via the neurotransmitter vasoactive intestinal polypeptide (VIP).

171 ent manner by dorsal AH neurons that produce vasoactive intestinal polypeptide (VIP).

172 the structurally similar mammalian peptide, vasoactive intestinal polypeptide (VIP).

173 zed the population, phenocopying the loss of vasoactive intestinal polypeptide (VIP).

174 ot for parvalbumin (PV), calretinin (CR), or vasoactive intestinal polypeptide (VIP).

175 N, physiological evidence suggests that only vasoactive intestinal polypeptide (VIP)/gastrin-releasin

176 ATP (1 mM), vasoactive intestinal polypeptide (VIP, 0.01-0.25 microM

177 Vasoactive intestinal polypeptide (VIP, 1 nmol) had no s

178 The GsPCR agonist, vasoactive intestinal polypeptide (VIP; 100 nM), rapidly

179 s of somatostatin(+) (SST) (MGE-derived) and vasoactive intestinal polypeptide(+) (VIP) (CGE-derived)

180 ed on immunocytochemistry, that synthesis of vasoactive intestinal polypeptide was increased upon lid

181 acetyltransferase, and substance P, whereas vasoactive intestinal polypeptide was more abundant in v